Generic Drug News and Research RSS Feed - Generic Drug News and Research

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.
Common drug for high blood pressure repurposed to treat soft tissue sarcoma in Europe

Common drug for high blood pressure repurposed to treat soft tissue sarcoma in Europe

A drug that's commonly used to treat high blood pressure is being repurposed for a rare tissue cancer in Europe. The medication, named propranolol, was recently granted Orphan Drug Designation by the European Commission. [More]
DaVita releases recap of 2016 accomplishments

DaVita releases recap of 2016 accomplishments

DaVita Inc., a leading independent medical group and a leading provider of kidney care services in the United States, today released a recap of major accomplishments for the company in 2016, marking its 16th year bringing quality of life to patients and teammates around the world. [More]
Researchers find wide price variability in generic heart failure drugs

Researchers find wide price variability in generic heart failure drugs

New research from Saint Louis University finds that the prices for commonly used generic heart failure drugs varies widely. [More]
Safety of generic oncology drugs in developing countries is uncertain, say researchers

Safety of generic oncology drugs in developing countries is uncertain, say researchers

Although generic oncology drugs can reduce patient costs and improve treatment access, the safety of these drugs in developing countries is uncertain, according to an international research team led by Dr. Charles Bennett, Josie M. Fletcher professor and chairman of the S.C. SmartState Center in Medication Safety and Efficacy at the College of Pharmacy at the University of South Carolina. [More]
Study provides insight into how weight-loss drug acts in the brain

Study provides insight into how weight-loss drug acts in the brain

A weight-loss drug dampened the response to food cues in regions of the brain associated with attention and emotion, leading to decreases in caloric intake, weight and body mass index (BMI), a team led by scientists at Beth Israel Deaconess Medical Center reported. [More]
Clinical trial finds pioglitazone drug safe and effective for NASH patients

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants. [More]
High-fructose diet during pregnancy may affect fetal growth

High-fructose diet during pregnancy may affect fetal growth

Consuming a high-fructose diet during pregnancy may cause defects in the placenta and restrict fetal growth, potentially increasing a baby's risk for metabolic health problems later in life, according to research in mice and people by a team at Washington University School of Medicine in St. Louis. [More]
Finding treatments for rare diseases: an interview with Dr Richard Thompson

Finding treatments for rare diseases: an interview with Dr Richard Thompson

It is estimated that around 400 rare diseases have licenced treatments, and a large proportion of these are a consequence of orphan drug legislation, which has helped to incentivise the production of drugs for small patient populations. [More]
First generic version of Crestor gets FDA approval

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets. [More]
Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc. [More]
Study confirms no detectable difference when switching between generics

Study confirms no detectable difference when switching between generics

While approved generics are required to be equivalent to their brand-named counterparts in terms of active ingredients, some may wonder if a switch between generics could cause problems for someone who relies on daily medication to control a severe, chronic condition, like seizures. [More]
Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg. [More]
Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study. [More]
Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). [More]
GATE opens for generic equivalent to glatiramer acetate in MS

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis. [More]
New national survey finds lack of COPD knowledge among patients

New national survey finds lack of COPD knowledge among patients

In a new national survey of chronic obstructive pulmonary disease (COPD) patients, Health Union reveals a surprising lack of awareness of risk factors and knowledge of diagnosis stage among patients. Results demonstrate a severe impact on quality of life, employment, and ability to afford treatment. [More]
Mylan announces launch of generic Namenda Tablets in U.S.

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets. [More]

ANI acquires 22 previously marketed generic drug products for $25 million from Teva Pharmaceuticals

ANI Pharmaceuticals, Inc. today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. [More]

CVS Health signs definitive agreement to acquire Target's pharmacy and clinic businesses for $1.9 billion

CVS Health Corporation and Target Corporation announced today that they have entered into a definitive agreement for CVS Health to acquire Target's pharmacy and clinic businesses for approximately $1.9 billion. Through this agreement, CVS Health will acquire Target's more than 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy. [More]
China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014. [More]
Advertisement
Advertisement